Variable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 50, Issue 8, 2009, Pages 1361-1368

  Weitzman, James ^a   Betancur, Monica ^a   Boissel, Laurent ^a   Rabinowitz, Arthur P ^b   Klein, Andreas ^a   Klingemann, Hans ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

ADCC; CLL; monoclonal antibodies; natural killer cells

Indexed keywords

CD20 ANTIBODY; CD22 ANTIGEN; CD23 ANTIGEN; EPRATUZUMAB; FC GAMMA RECEPTOR IIIA; FC RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LUMILIXIMAB; MEMBRANE ANTIGEN; RITUXIMAB; UNCLASSIFIED DRUG; VELTUZUMAB; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD22 PROTEIN, HUMAN; CD52 ANTIGEN; GLYCOPROTEIN; HLL2 AGENT; HYBRID PROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMMU 106; MONOCLONAL ANTIBODY IMMU-106; TUMOR ANTIGEN;

ADULT; ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; CELL KILLING; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DNA DETERMINATION; EFFECTOR CELL; GENETIC TRANSFECTION; GENOTYPE; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; COMPARATIVE STUDY; GENETICS; IMMUNOLOGY; IN VITRO STUDY; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, CD22; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENOTYPE; GLYCOPROTEINS; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 77649313015     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903026500     Document Type: Article

References (34)

1. Shanafelt TD, Byrd JC, Call TG, et al. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med 2006;145:435-447. (Pubitemid 46768575)
2. Abbott BL. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 2006;11:21-30. (Pubitemid 43152683)
3. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694-704. (Pubitemid 46224168)
4. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997. (Pubitemid 26189840)
5. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother 2006;55:188-196. (Pubitemid 41682591)
6. Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 2005;23:6325-6332. (Pubitemid 46218842)
7. Byrd JC, Castro J, O'Brien S, et al. Comparison of results from a phase 1/2 study of lumiliximab (anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. Blood 2006;108:14a.
8. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008;359:613-626.
9. Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-2642. (Pubitemid 39434941)
10. Iannello A, Ahmad A. Role of antibody-dependent cellmediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005;24:487-499. (Pubitemid 43096997)
11. Koene HR, Kleijer M, Algra J, et al. Fc γRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc γRIIIa, independently of the Fc γRIIIa-48L/R/H phenotype. Blood 1997;90:1109-1114. (Pubitemid 27314146)
12. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximabdependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-4669. (Pubitemid 38856941)
13. Hatjiharissi E, Xu L, Santos DD, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{γ}RIIIa-158 V/V and V/F polymorphism. Blood 2007;110:2561-2564. (Pubitemid 47523179)
14. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002;99:754-758. (Pubitemid 34525533)
15. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23:474-481. (Pubitemid 46224224)
16. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-3947. (Pubitemid 46606207)
17. van der Kolk LE, de Haas M, Grillo-Lopez AJ, et al. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 2002;16:693-699. (Pubitemid 34449752)
18. Chang DH, Liu N, Klimek V, et al. Enhancement of liganddependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:618-621. (Pubitemid 44061362)
19. Moga E, Alvarez E, Canto E, et al. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol 2008;36:69-77. (Pubitemid 350266964)
20. Gowda A, Roda J, Hussain SR, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 2008;111:4723-4730.
21. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006;103:4005-4010.
22. Wang SY, Racila E, Taylor RP, et al. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008;111:1456-1463. (Pubitemid 351213433)
23. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:2868-2878. (Pubitemid 38509167)
24. Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006;24:3880-3886. (Pubitemid 46630735)
25. Papamichail M, Perez SA, Gritzapis AD, et al. Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother 2004;53:176-186. (Pubitemid 38328040)
26. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994;8:652-658. (Pubitemid 24133034)
27. Binyamin L, Alpaugh RK, Hughes TL, et al. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol 2008;180:6392-6401.
28. Robins RA. Flow cytometric analysis of cell surface antigen density. Methods Mol Biol 1998;80:319-336.
29. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-191. (Pubitemid 28185349)
30. Coleman M, Goldenberg DM, Siegel AB, et al. Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res 2003;9(10 Part 2):3991S-3994S. (Pubitemid 37169206)
31. Pathan NI, Chu P, Hariharan K, et al. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 2008;111:1594-1602. (Pubitemid 351213450)
32. Farag SS, Flinn IW, Modali R, et al. Fc γ RIIIa and Fc γ RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004;103:1472-1474. (Pubitemid 38168664)
33. Maki G, Hayes GM, Naji A, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implications of HLA-G. Leukemia 2008:22;998-1006. (Pubitemid 351689882)
34. Boissel L, Betancur M, Wels WS, et al. Transfection with mRNA for CD19 specific antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res, in press.